Safety and efficacy of B-cell therapy in older people with multiple sclerosis

Puntos clave

• B-cell therapy demonstrated both safety and efficacy over a 44-month period in older adults.
• Participants had a mean age of 63, with outcomes comparable to younger populations.
• Monitoring adverse effects is crucial, as immunoglobulin decline and therapy discontinuation occurred.
• The findings suggest that B-cell therapy could be a viable treatment option for older adults with MS.